Latest moves in biopharma leadership include Mark Winderlich becoming chief development officer at Hookipa Pharma and Dianne Hol leaving AstraZeneca to join Lundbeck, where she becomes EVP people and organization.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Pascal Soriot, CEO of AstraZeneca, joins Agilent Technologies' board, plus Zealand Pharma acquires chief development officer from UCB Biopharma.
Recent moves in the industry include new C-suite hires at Janux Therapeutics, BlueSphere Bio and Hansa Biopharma, plus Syndax Pharmaceuticals gets new chief medical officer from Bristol Myers Squibb.
Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.
Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.
CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.
Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.
McKinsey senior partner Vivek Pandit talks to Scrip about some of the intricacies underlying the key findings of a study on pharma’s workforce gender gap in India. Women’s representation starts low at entry level, peaks at senior manager positions and falls off again for C-suite roles, this found.
